HUMAN WILD-TYPE P53 ADOPTS A UNIQUE CONFORMATIONAL AND PHOSPHORYLATION STATE INVIVO DURING GROWTH ARREST OF GLIOBLASTOMA CELLS

被引:0
|
作者
ULLRICH, SJ [1 ]
MERCER, WE [1 ]
APPELLA, E [1 ]
机构
[1] THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107
关键词
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The wild-type (wt) human tumor-suppressor gene product, p53, and its mutant form have been analysed in an in vivo system in which the inducible expression of wt p53 results in growth arrest in the G1 phase of the cell cycle. Two major pools of p53 are detected after wt p53 expression by their differential reactivity with the p53 monoclonal antibodies PAb 421 and 1801 as well as the mutant and wt-specific monoclonal antibodies PAb 240 and 1620; one pool contains wt and mutant p53 and is characterized as having a mutant conformation, whereas the other pool contains only wt p53 with a wt conformation. As G1 arrest is entered, the amount of wt p53 associated with the mutant pool decreases, such that by 12 h free wt and mutant p53 are the - major pools. Two-dimensional gel analysis of the p53 pools revealed that free wt p53 is phosphorylated to a greater degree than mutant p53, which correlated with the loss of the PAb 421 epitope on wt p53. In summary, the ability of wt p53 to exert an antiproliferative effect correlates with the presence of a unique conformational state of wt p53 characterized by increased phosphorylation and the loss of both the PAb 421 epitope and association with mutant p53 pool, whereas mutant p53 is unable to assume this conformational state.
引用
收藏
页码:1635 / 1643
页数:9
相关论文
共 50 条
  • [41] An experimental vaccine expressing wild-type p53 induces protective immunity against glioblastoma cells with high levels of endogenous p53
    Blaszczyk-Thurin, M
    O, I
    Ertl, HCJ
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2002, 56 (04) : 361 - 375
  • [42] Effects of adenoviral wild-type p53 gene transfer in p53 -mutated lymphoma cells
    Peter Buttgereit
    Frank Schakowski
    Angela Märten
    Karsten Brand
    Sabine Renoth
    Carsten Ziske
    Björn Schöttker
    Oliver Ebert
    Roland Schroers
    Ingo GH Schmidt-Wolf
    Cancer Gene Therapy, 2001, 8 : 430 - 439
  • [43] p53 transactivation domain phosphorylation level is associated with poor clinicopathological features of wild-type p53 HCCs
    Kim, Hyeon-Seop
    Jung, Guhung
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 345 - 345
  • [44] Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene
    Lang, FF
    Yung, WKA
    Raju, U
    Libunao, F
    Terry, NHA
    Tofilon, PJ
    JOURNAL OF NEUROSURGERY, 1998, 89 (01) : 125 - 132
  • [45] EXPRESSION OF WILD-TYPE P53 IS NOT COMPATIBLE WITH CONTINUED GROWTH OF P53-NEGATIVE TUMOR-CELLS
    JOHNSON, P
    GRAY, D
    MOWAT, M
    BENCHIMOL, S
    MOLECULAR AND CELLULAR BIOLOGY, 1991, 11 (01) : 1 - 11
  • [46] WILD-TYPE HUMAN P53 ACTIVATES THE HUMAN EPIDERMAL GROWTH-FACTOR RECEPTOR PROMOTER
    DEB, SP
    MUNOZ, RM
    BROWN, DR
    SUBLER, MA
    DEB, S
    ONCOGENE, 1994, 9 (05) : 1341 - 1349
  • [47] Wild-type p53 activates SAP expression in lymphoid cells
    N Nagy
    M Takahara
    J Nishikawa
    J C Bourdon
    L L Kis
    G Klein
    E Klein
    Oncogene, 2004, 23 : 8563 - 8570
  • [48] Wild-type p53 activates SAP expression in lymphoid cells
    Nagy, N
    Takahara, M
    Nishikawa, J
    Bourdon, JC
    Kis, LL
    Klein, G
    Klein, E
    ONCOGENE, 2004, 23 (53) : 8563 - 8570
  • [49] Inactivation of Wild-Type p53 by Asparagine Endopeptidase in Glioblastoma: An Opportunity to Target the "Undruggable"
    Manfredi, James J.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2020, 112 (04): : 327 - 329
  • [50] WILD-TYPE p53 DRIVES A MESENCHYMAL PHENOTYPE AFTER TREATMENT OF PRIMARY GLIOBLASTOMA
    Li, Li
    Vemireddy, Vamsidhara
    Mashimo, Tomoyuki
    Huntington, Paula
    Mickey, Bruce
    Maher, Elizabeth
    Bachoo, Robert
    Piccirillo, Sara G. M.
    NEURO-ONCOLOGY, 2017, 19 : 258 - 259